Vetzigenic is transforming the treatment of challenging diseases in pets with innovative technology that produces best-in-class antibody therapies.
Vetigenix is a clinical stage animal health biotechnology company dedicated to advancement in veterinary medicine with cutting-edge antibody therapies. We develop targeted treatments for companion animals for cancer and chronic diseases, and leverage our proprietary phage display technology to create safer and more effective treatments tailored to the unique biology of your pet.
Founded by experts in veterinary and human medicine, Speed Genics is committed to revolutionizing pet healthcare by bringing the power of biotechnology to veterinary practice. Our innovative approach allows us to develop new treatments that improve your pet treatment outcomes and improve your veterinarian options.
Our mission
At Vettegenics, our mission is simple. It’s about ensuring your pet lives the best. We address some of the most pressing illnesses in veterinary medicine and set new standards for treatment and care. By advancing species-specific antibodies, we create treatments that maximize efficacy while minimizing side effects, ultimately improving the health of pets around the world.
Our Technology
At the heart of innovation is the Canibody™ platform, a completely dog phage display library that accelerates the discovery and development of antibody tailored to pets. Unlike treatments adapted from human or mouse sources, our species-specific antibodies provide greater safety and efficacy, ensuring that your pet receives the best possible care.
Key benefits of the Canibody™ platform include:
Width and Variety: The only fully dog-derived platform featuring billions of unique antibody genes to maximize therapeutic potential. Precision targeting: A treatment designed to make the most of disease mechanisms. Improved Safety: Our antibodies, made from real dog genetic material, minimize the risks and side effects of immunogenicity. Rapid and cost-effective development: A streamlined discovery process reduces costs and drives the transition from research to clinical use.
This technology provides the foundation for innovative treatment solutions and provides veterinarians with new tools to combat diseases that were previously difficult to manage.
Our Clinical Pipeline
Speed is primarily focused on addressing key veterinary challenges.
Oncology
Cancer remains the leading cause of death in pets, and current treatment options are often limited in efficacy. Vetzigenic is developing a pipeline of novel immunotherapies to activate the immune system and combat cancer more effectively. Our leading candidates, VGS-001 (Anti-CCTLA4) and VGS-002 (Anti-CPD1), offer the potential to improve survival and quality of life for a variety of tumor types.
Autoimmune and chronic diseases
Beyond cancer, our research extends to antibody therapy for autoimmune and inflammatory conditions that many pets suffer from. By targeting major disease pathways, our biology may provide lasting relief and long-term health outcomes.
Our Continuous Development
Speed is committed to rigorous scientific research and evidence-based development. Our portfolio includes multiple antibody candidates at different stages of research and development, with an emphasis on translation medicine to bring innovative treatments from the lab to veterinary clinics. Some areas include allergies, obesity, and feline oncology.
We are working with leading veterinary research institutes to conduct clinical trials to assess the safety and efficacy of treatments in real-world veterinary environments. Partnerships with academic institutions, CROs and veterinary oncologists ensure that they are developing treatments that meet both safety and efficacy criteria.
The future of veterinary medicine
As veterinary medicine continues to evolve, the demand for safe, effective, targeted therapies will be greater than ever. Vettgenic is at the forefront of this transformation, leveraging the power of biotechnology to develop next-generation treatments for pets.
Through continuous innovation, strategic partnerships and a steady commitment to improving pet health, we are shaping the future of veterinary medicine. Our goal is to expand the range of antibody-based therapies and enable life-saving treatments that will increase happiness and longevity everywhere for pets.
Revolutionize your pet’s health
When we blasphem, we believe that every pet deserves the best possible care. Whether you are a pet owner, veterinarian expert or researcher, we encourage you to participate in our mission to transform veterinary medicine through antibody-based therapy.
Learn more about our work, explore clinical trial opportunities, and stay up to date with the latest advances in managing the most challenging illnesses at www.vetigenics.com.
Together, your pets can live their best life.
This article will also be featured in the 21st edition of Quarterly Publication.
Source link
